Phase II Clinical trial of GTC in Men on Active Surveillance
GTC 在男性主动监测中的 II 期临床试验
基本信息
- 批准号:10177964
- 负责人:
- 金额:$ 61.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-06-01 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:5 Alpha-Reductase InhibitorAdherenceAdoptionAdverse eventAnxietyApoptosisBioavailableBiodistributionBiologicalBiological AvailabilityBiological MarkersBiopsyCASP3 geneCell SurvivalCessation of lifeCharacteristicsChemopreventionChemopreventive AgentClinicalClinical TrialsConflict (Psychology)Core BiopsyDetectionDevelopmentDietary HistoryDiseaseDisease ProgressionDoseDouble-Blind MethodDutasterideEffectivenessEligibility DeterminationEpidemiologyEpigallocatechin GallateEvaluationExperimental DesignsExposure toFinasterideFormulationFutureGene ExpressionGenesGleason Grade for Prostate CancerGreen teaHistologicIn VitroIncidenceInduction of ApoptosisInterventionKineticsLife StyleMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMental DepressionMolecularMonitorMorbidity - disease rateNF-kappa BOutcomePathway interactionsPatientsPatternPeriodicityPharmacologyPhasePhase II Clinical TrialsPhase III Clinical TrialsPlacebosPlasmaProliferation MarkerProstate AdenocarcinomaProstate-Specific AntigenProteasome InhibitionQuality of lifeRandomizedRandomized Clinical TrialsRegulationReportingResearchRiskSafetySamplingScreening for Prostate CancerSignal TransductionStandardizationSubgroupTestingTherapeutic InterventionTimeTissuesToxic effectUncertaintyValidationVariantbasecancer chemopreventioncarcinogenesiscyclin-dependent kinase inhibitor 1Bdensitydesignearly phase trialepicatechinepicatechin gallategallocatecholgut microbiomeindexinginhibitor/antagonistlower urinary tract symptomsmenmetabolomicsmetatranscriptomicsmicrobiotanoveloncotypeoverexpressionovertreatmentpersonalized approachpillpost interventionpre-clinicalpreventprostate biopsyprostate cancer cellprostate cancer progressionprostate cancer riskprostate carcinogenesisserum PSAtumor
项目摘要
Abstract:
The era of screening for prostate cancer (PCa) using serum prostate specific antigen (PSA) has led to an
increase in the detection of low-grade prostate cancers that pose little risk of either metastatic spread or death.
Additionally, these men may be now exposed to morbidities of over treatment with little or no benefit of
cancer-specific survival. Active surveillance (AS) has thus evolved as a recommended management strategy for
men with low grade disease, providing the benefit of an individualized approach of carefully monitoring
disease progression, sufficient to permit timely therapeutic intervention. However, concerns about under-
grading, variations in criteria for AS eligibility, patient reported anxiety, depression, doubts about the possible
progression of the disease as well as higher decisional conflict regarding selection of AS, men on AS have been
reported to ultimately opt for treatment without any major change in tumor characteristics. On the other hand,
men on AS are a subgroup, who are highly motivated and eager to make positive lifestyle
changes to further reduce their risk of PCa progression- providing an opportunity for
chemoprevention. Chemoprevention strategies with 5-alpha-reductase inhibitors significantly reduced the
risk of prostate cancer progression. However their use was also associated with increased detection of high-
grade disease, severely limiting their clinical adoption. Currently, there is a paucity of research that
systematically examines agents for chemoprevention in men on AS. Green tea catechins (GTC)
influence several hallmarks of carcinogenesis, including prostate carcinogenesis, with an acceptable safety
profile, making them attractive candidates for PCa chemoprevention. Several epidemiological, in vitro,
preclinical and early phase trials completed by our team and others have shown that the GTC are potent
inhibitors of PCa carcinogenesis through multiple mechanisms, bioavailable in tissue and plasma, reduces
several intermediate biomarkers implicated in PCa progression and without toxicities at these doses. Based on
the available evidence, we hypothesize that men with biopsy proven adenocarcinoma of the prostate who
meet the criteria for AS, who receive GTC at a dose of 800 mg EGCG per day (vs. placebo) for 24 months, will
have a significantly decreased rate of clinical progression. We will test this hypothesis using a rigorous
experimental design in a phase II, randomized clinical trial to evaluate the safety, effectiveness and
potential mechanism by which GTC modulates clinical progression and the related biological biomarkers
relevant to PCa progression in men on AS for PCa. Positive results from this study will be critical
to inform development a phase III clinical trial and ultimately provide a strategy for secondary chemoprevention
in men on AS, for whom, currently, there are no options for reducing risk of progression to PCa.
摘要:
使用血清前列腺特异性抗原(PSA)筛查前列腺癌(PCA)的时代已经导致了
增加对转移扩散或死亡风险很小的低级别前列腺癌的检测。
此外,这些人现在可能暴露在过度治疗的病症中,而很少或根本没有受益。
癌症特有的存活率。因此,主动监视(AS)已演变为一种推荐的管理策略
患有低级别疾病的男性,提供了仔细监测的个性化方法的好处
疾病进展,足以允许及时的治疗干预。然而,对不足的担忧-
分级,AS资格标准的变化,患者报告的焦虑,抑郁,对可能的
疾病的进展以及关于选择AS的更高决策冲突,AS上的男性一直如此
据报道,最终选择治疗,肿瘤特征没有任何重大变化。另一方面,
AS上的男性是一个亚群体,他们非常有动力,渴望创造积极的生活方式
进一步降低其PCA进展风险的变化-为
化学预防。使用5-α还原酶抑制剂的化学预防策略显著减少了
前列腺癌进展的风险。然而,它们的使用也与高血糖的检测增加有关。
严重限制了它们的临床应用。目前,很少有研究表明,
系统地检查AS男性的化学预防药物。绿茶儿茶素(GTC)
以可接受的安全性影响癌症发生的几个特征,包括前列腺癌的发生
个人资料,使它们成为PCA化学预防的有吸引力的候选者。几个流行病学的,体外的,
我们团队和其他人完成的临床前和早期试验表明,GTC是有效的
通过多种机制抑制前列腺癌的发生,在组织和血浆中生物可用,减少
几个中间生物标志物参与了前列腺癌的进展,并且在这些剂量下没有毒性。基于
根据现有的证据,我们假设,接受活检的男性被证实患有前列腺癌
符合AS标准的患者,每天服用GTC 800毫克EGCG(与安慰剂相比),持续24个月,将
临床进展率显著降低。我们将使用严格的
试验设计为II期随机临床试验,以评估其安全性、有效性和
GTC调控临床进展的可能机制及相关生物标志物
与男性前列腺癌的进展有关,与前列腺癌有关。这项研究的积极结果将是至关重要的
为第三阶段临床试验的发展提供信息,并最终提供二次化学预防的战略
对于患有AS的男性来说,目前还没有降低进展到PCa风险的选择。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NAGI B. KUMAR其他文献
NAGI B. KUMAR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NAGI B. KUMAR', 18)}}的其他基金
Phase II Clinical trial of GTC in Men on Active Surveillance
GTC 在男性主动监测中的 II 期临床试验
- 批准号:
10424498 - 财政年份:2019
- 资助金额:
$ 61.52万 - 项目类别:
Phase II Clinical trial of GTC in Men on Active Surveillance
GTC 在男性主动监测中的 II 期临床试验
- 批准号:
10673170 - 财政年份:2019
- 资助金额:
$ 61.52万 - 项目类别:
Phase II Clincal Trial of Purified Isofavones in Prostate Cancer: Comparing Safet
纯化异黄酮治疗前列腺癌的 II 期临床试验:比较 Safet
- 批准号:
8412706 - 财政年份:2013
- 资助金额:
$ 61.52万 - 项目类别:
Phase II Clincal Trial of Purified Isofavones in Prostate Cancer: Comparing Safet
纯化异黄酮治疗前列腺癌的 II 期临床试验:比较 Safet
- 批准号:
8374882 - 财政年份:2012
- 资助金额:
$ 61.52万 - 项目类别:
Phase II Clincal Trial of Purified Isofavones in Prostate Cancer: Comparing Safet
纯化异黄酮治疗前列腺癌的 II 期临床试验:比较 Safet
- 批准号:
7686500 - 财政年份:2009
- 资助金额:
$ 61.52万 - 项目类别:
Phase II Clinical Trial of Polyphenon E in Prostate Cancer
Polyphenon E治疗前列腺癌的II期临床试验
- 批准号:
7886914 - 财政年份:2007
- 资助金额:
$ 61.52万 - 项目类别:
Phase II Clinical Trial of Polyphenon E in Prostate Cancer
Polyphenon E治疗前列腺癌的II期临床试验
- 批准号:
8075655 - 财政年份:2007
- 资助金额:
$ 61.52万 - 项目类别:
Phase II Clinical Trial of Polyphenon E in Prostate Cancer
Polyphenon E治疗前列腺癌的II期临床试验
- 批准号:
7628623 - 财政年份:2007
- 资助金额:
$ 61.52万 - 项目类别:
Phase II Clinical Trial of Polyphenon E in Prostate Cancer
Polyphenon E治疗前列腺癌的II期临床试验
- 批准号:
7689525 - 财政年份:2007
- 资助金额:
$ 61.52万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 61.52万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 61.52万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 61.52万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 61.52万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 61.52万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 61.52万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 61.52万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 61.52万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 61.52万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 61.52万 - 项目类别:
Fellowship Programs